Rheumatology Network News Roundup: JAK Inhibitors and Rheumatoid Arthritis

Only 12% of PsA Patients Say Disease Is Under ControlПодробнее

JAKi in Rheumatoid Arthritis: Cancer and Cardiovascular RisksПодробнее

The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)Подробнее

Discussing Rheumatology: JAK Inhibitor Monotherapy in RAПодробнее

ACR24 Rheumatology RoundupПодробнее

JAK inhibitors in rheumatic diseasesПодробнее

Malignancy and infection risk with JAK inhibitors in RA patients | Hans BijlsmaПодробнее

When to use a JAK inhibitor in RA: Dr. Janet PopeПодробнее

Repurposing rheumatology drugs for COVID-19: JAK inhibitorsПодробнее

JAK vs TNF inhibitor Infections in RAПодробнее

Discussing Rheumatology: JAK InhibitorsПодробнее

Forum LIVE: Patient-Reported Outcomes in Rheumatoid Arthritis Patients Receiving JAK InhibitorsПодробнее

Discussing Rheumatology: JAKi and TNFiПодробнее

RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?Подробнее

RheumNow Rheumatology RoundupПодробнее

EULAR RoundupПодробнее

RA: One JAK to Rule Them All?Подробнее

Rheumatology News Roundup: Mobile Apps in Healthcare ResearchПодробнее